129101-54-8 | (2R,3R)-2,3-dihydroxybutanedioic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate

Packsize	Purity	Availability	Price	Discounted Price
1g	97%	in stock	$45.00	$32.00
5g	97%	in stock	$147.00	$103.00
25g	97%	in stock	$449.00	$315.00
100g	97%	in stock	$1,319.00	$923.00

Description

• Catalog Number: AA44969
• Chemical Name: (2R,3R)-2,3-dihydroxybutanedioic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
• CAS Number: 129101-54-8
• Molecular Formula: C18H28N2O8
• Molecular Weight: 400.4235
• MDL Number: MFCD03700731
• SMILES: O[C@H]([C@H](C(=O)O)O)C(=O)O.CCN(C(=O)Oc1cccc(c1)[C@@H](N(C)C)C)C

Computed Properties

• Complexity: 402
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 8

Literature

• Rivastigmine for vascular cognitive impairment.

  The Cochrane database of systematic reviews 20130531

• Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors.

  Chemico-biological interactions 20130325

• A rivastigmine-precipitated manic episode in a patient with Alzheimer-type dementia.

  International psychogeriatrics 20121001

• Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer's disease.

  Journal of the American Geriatrics Society 20121001

• Rivastigmine in the treatment of postoperative delirium: a pilot clinical trial.

  International journal of geriatric psychiatry 20120901

• Treatment of delirium following cardiac surgery.

  Journal of cardiac surgery 20120901

• Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.

  Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 20120901

• Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120830

• Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking.

  Molecules (Basel, Switzerland) 20120824

• Amphiphilic polyaspartamide copolymer-based micelles for rivastigmine delivery to neuronal cells.

  Drug delivery 20120801

• Protective role of curcumin on colchicine-induced cognitive dysfunction and oxidative stress in rats.

  Human & experimental toxicology 20120701

• Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120701

• Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120701

• Effect of some medicinal plant extracts on the oxidative stress status in Alzheimer's disease induced in rats.

  European review for medical and pharmacological sciences 20120701

• Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study.

  Journal of clinical psychopharmacology 20120601

• Estimation of financial burden due to oversupply of medications for chronic diseases.

  Asia-Pacific journal of public health 20120501

• Chronic treatment with rivastigmine in patients with Alzheimer's disease: a study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation.

  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20120501

• Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20120501

• Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?

  American journal of Alzheimer's disease and other dementias 20120501

• Rivastigmine reduces 'Likely to use methamphetamine' in methamphetamine-dependent volunteers.

  Progress in neuro-psychopharmacology & biological psychiatry 20120427

• Hallucinations treated with rivastigmine in Creutzfeldt-Jakob disease.

  Fundamental & clinical pharmacology 20120401

• New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

  British journal of clinical pharmacology 20120401

• Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20120401

• Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.

  The Annals of pharmacotherapy 20120401

• Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

  The Cochrane database of systematic reviews 20120314

• Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats.

  Current Alzheimer research 20120301

• Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

  Cold Spring Harbor perspectives in medicine 20120301

• aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.

  The journal of nutrition, health & aging 20120201

• Development of a capillary electrophoresis-mass spectrometry method for the determination of rivastigmine in human plasma--optimization of the limits of detection and quantitation.

  Electrophoresis 20120201

• A fatal outcome after unintentional overdosing of rivastigmine patches.

  Current drug safety 20120201

• Acetylcholinesterase inhibitors for schizophrenia.

  The Cochrane database of systematic reviews 20120118

• Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.

  Journal of pharmaceutical and biomedical analysis 20120105

• [Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120101

• Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease.

  Expert review of neurotherapeutics 20120101

• Pisa syndrome secondary to rivastigmine: a case report.

  La Clinica terapeutica 20120101

• Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.

  Journal of Alzheimer's disease : JAD 20120101

• The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

  Health technology assessment (Winchester, England) 20120101

• [New anti-AD drugs--their possibilities and issues].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20120101

• Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia.

  Clinical neuropharmacology 20120101

• Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.

  Journal of Alzheimer's disease : JAD 20120101

• Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers.

  Progress in neuro-psychopharmacology & biological psychiatry 20111201

• Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

  International journal of geriatric psychiatry 20111201

• [Rivastigmine].

  Nihon rinsho. Japanese journal of clinical medicine 20111201

• Preparation and evaluation of injectable sustained-release microspheres of rivastigmine.

  Journal of controlled release : official journal of the Controlled Release Society 20111130

• Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.

  Behavioural brain research 20111120

• Expressing findings from meta-analyses of continuous outcomes in terms of risks.

  Statistics in medicine 20111110

• Effect of cholinergic stimulation in early Alzheimer's disease - functional imaging during a recognition memory task.

  Current Alzheimer research 20111101

• BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

  European journal of clinical pharmacology 20111101

• The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20111101

• Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

  Drugs & aging 20111101

• Effective pharmacological management of Alzheimer's disease.

  The American journal of managed care 20111101

• Pharmacologic treatment for memory disorder in multiple sclerosis.

  The Cochrane database of systematic reviews 20111005

• Cholinesterase inhibitor initiation in hospital setting.

  Journal of the American Geriatrics Society 20111001

• Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals.

  Pharmacology, biochemistry, and behavior 20110901

• Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.

  Expert opinion on investigational drugs 20110901

• Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20110901

• Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.

  American journal of Alzheimer's disease and other dementias 20110901

• [Newly approved drugs for Alzheimer disease: effectiveness and limitation].

  Brain and nerve = Shinkei kenkyu no shinpo 20110801

• New drugs for Alzheimer's disease in Japan.

  Psychiatry and clinical neurosciences 20110801

• Bioequivalence evaluation of two brands of rivastigmine of different salt forms, an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy Beagle dogs.

  Die Pharmazie 20110801

• A case of rivastigmine toxicity caused by transdermal patch.

  The American journal of emergency medicine 20110701

• Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.

  Geriatrics & gerontology international 20110701

• New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.

  Drug development and industrial pharmacy 20110701

• [Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].

  Psychiatrische Praxis 20110701

• [Prescription differences of dementia drugs in urban and rural areas in Germany].

  Psychiatrische Praxis 20110701

• Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.

  Current medical research and opinion 20110701

• Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.

  CNS drugs 20110701

• A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.

  International journal of clinical practice 20110701

• Rivastigmine associated hyponatremia in an older patient with Alzheimer's disease.

  Journal of the American Geriatrics Society 20110701

• [Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].

  Yao xue xue bao = Acta pharmaceutica Sinica 20110701

• Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.

  Drugs 20110618

• Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.

  Neurologia (Barcelona, Spain) 20110601

• Rivastigmine reverses aluminum-induced behavioral changes in rats.

  European journal of pharmacology 20110601

• First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine?

  American journal of clinical dermatology 20110601

• Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.

  International journal of geriatric psychiatry 20110501

• Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.

  The journal of nutrition, health & aging 20110501

• Rivastigmine patches: fatal overdoses.

  Prescrire international 20110501

• Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease.

  Therapeutic delivery 20110501

• Switching cholinesterase inhibitors in older adults with dementia.

  International psychogeriatrics 20110401

• Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.

  International journal of clinical practice 20110401

• Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.

  International journal of geriatric psychiatry 20110401

• [Delirium in the elderly].

  Deutsche medizinische Wochenschrift (1946) 20110401

• Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.

  Prescrire international 20110401

• Cholinesterase inhibitor treatment in patients with delirium.

  Lancet (London, England) 20110312

• Cholinesterase inhibitor treatment in patients with delirium.

  Lancet (London, England) 20110312

• Cholinesterase inhibitor treatment in patients with delirium.

  Lancet (London, England) 20110312

• Cholinesterase inhibitor treatment in patients with delirium.

  Lancet (London, England) 20110312

• Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS/MS.

  Biomedical chromatography : BMC 20110301

• Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.

  International journal of geriatric psychiatry 20110301

• Alzheimer's drug proves ineffective for delirium.

  The Harvard mental health letter 20110301

• Acetylcholine and chronic vasculopathy in rat renal allografts.

  Transplantation 20110215

• Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.

  The Gerontologist 20110201

• Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.

  American journal of Alzheimer's disease and other dementias 20110201

• Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Evidence is not satisfactory.

  Deutsches Arzteblatt international 20110201

• Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition: different effects of donepezil and rivastigmine.

  Behavioural pharmacology 20110201

• Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.

  Alzheimer disease and associated disorders 20110101

• Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.

  Alzheimer disease and associated disorders 20110101

• [Somatoform disorder or neurological syndrome? Complex mental and movement disorder and autonomic dysfunction in a 65-year-old patient - Case 1/2011].

  Deutsche medizinische Wochenschrift (1946) 20110101

• Cutaneous reactions to transdermal therapeutic systems.

  Dermatitis : contact, atopic, occupational, drug 20110101

• Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons.

  PloS one 20110101

• Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20110101

• Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature.

  Cardiovascular toxicology 20101201

• Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia.

  CNS neuroscience & therapeutics 20101201

• Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.

  American journal of Alzheimer's disease and other dementias 20101201

• Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up.

  Journal of child and adolescent psychopharmacology 20101201

• Delirium treatment: an unmet challenge.

  Lancet (London, England) 20101127

• Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.

  Lancet (London, England) 20101127

• Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.

  Drugs & aging 20101101

• Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20101001

• The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.

  Current medical research and opinion 20101001

• Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

  Learning & memory (Cold Spring Harbor, N.Y.) 20101001

• Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.

  Deutsches Arzteblatt international 20101001

• [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].

  MMW Fortschritte der Medizin 20100916

• Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20100901

• Current treatments for patients with Alzheimer disease.

  The Journal of the American Osteopathic Association 20100901

• Modern care for patients with Alzheimer disease: rationale for early intervention.

  The Journal of the American Osteopathic Association 20100901

• Chemoenzymatic asymmetric total synthesis of (S)-Rivastigmine using omega-transaminases.

  Chemical communications (Cambridge, England) 20100814

• Management of inappropriate sexual behaviors in dementia: a literature review.

  International psychogeriatrics 20100801

• Rivastigmine in the treatment of delirium in older people: a pilot study.

  International psychogeriatrics 20100801

• Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.

  CNS neuroscience & therapeutics 20100801

• Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.

  American journal of Alzheimer's disease and other dementias 20100801

• Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease.

  Biomaterials 20100801

• Predictors of adherence among Alzheimer's disease patients receiving oral therapy.

  Current medical research and opinion 20100801

• Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

  Drugs & aging 20100801

• Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization.

  Allergy 20100701

• Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.

  Pharmacological research 20100601

• Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.

  American journal of Alzheimer's disease and other dementias 20100601

• How do we treat people with dementia in Croatia.

  Psychiatria Danubina 20100601

• [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].

  Tijdschrift voor gerontologie en geriatrie 20100601

• Study of rivastigmine for delirium in intensive care is stopped after deaths.

  BMJ (Clinical research ed.) 20100528

• Chemoenzymatic synthesis of rivastigmine via dynamic kinetic resolution as a key step.

  The Journal of organic chemistry 20100507

• Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease.

  Journal of neurology, neurosurgery, and psychiatry 20100501

• Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).

  Current medical research and opinion 20100501

• Anticholinesterase duration in the Australian veteran population.

  The Australian and New Zealand journal of psychiatry 20100501

• Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product.

  Drug testing and analysis 20100501

• Identification and characterization of new impurities in rivastigmine.

  Die Pharmazie 20100501

• [Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].

  Neurologia (Barcelona, Spain) 20100501

• Agrypnia with nocturnal confusional behaviors in dementia with Lewy bodies: immediate efficacy of rivastigmine.

  Movement disorders : official journal of the Movement Disorder Society 20100415

• Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease.

  Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20100415

• Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

  International journal of geriatric psychiatry 20100401

• A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.

  Acta neurologica Scandinavica 20100401

• Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.

  International journal of clinical practice 20100401

• Cholinesterase inhibitors and delirium after cardiac surgery.

  Critical care medicine 20100401

• Transdermal rivastigmine for Alzheimer's disease: skin deep or scratching the surface?

  International journal of clinical practice 20100401

• Treatment of apathy in Alzheimer's disease with transdermal rivastigmine: report of three cases.

  Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20100301

• A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease.

  Journal of neurochemistry 20100201

• A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

  Current medical research and opinion 20100201

• Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

  CNS drugs 20100201

• Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.

  Clinical drug investigation 20100101

• Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.

  Expert opinion on drug safety 20100101

• Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.

  CNS neuroscience & therapeutics 20100101

• Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.

  International journal of clinical practice 20100101

• Improvement of cognitive dysfunction with high-dose rivastigmine.

  Psychosomatics 20100101

• Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20100101

• Frontotemporal dementia and pharmacologic interventions.

  The Journal of neuropsychiatry and clinical neurosciences 20100101

• Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.

  Journal of Alzheimer's disease : JAD 20100101

• Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2).

  Die Pharmazie 20100101

• Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.

  Dementia and geriatric cognitive disorders 20100101

• Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.

  Dementia and geriatric cognitive disorders 20100101

• Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.

  Dementia and geriatric cognitive disorders 20100101

• Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report.

  BMC psychiatry 20100101

• Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.

  BMC psychiatry 20100101

• Neurovascular coupling in Parkinson's disease patients: effects of dementia and acetylcholinesterase inhibitor treatment.

  Journal of Alzheimer's disease : JAD 20100101

• [Rivastigmine in the treatment of dementia: from the symptomatic effect to neuroprotection].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

• [Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

• An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke.

  Functional neurology 20100101

• [Efficacy and safety of rivastigmine (exelon) in the confusion syndrome in the acute phase of ischemic stroke].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

• [Cholinesterase inhibitors for treating dementia. Review].

  Vertex (Buenos Aires, Argentina) 20100101

• Phospholipase C beta 4 in the medial septum controls cholinergic theta oscillations and anxiety behaviors.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20091209

• Neurovascular coupling in Alzheimer patients: effect of acetylcholine-esterase inhibitors.

  Neurobiology of aging 20091201

• International price comparisons of Alzheimer's drugs: a way to close the affordability gap.

  International psychogeriatrics 20091201

• Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

  The Journal of pharmacology and experimental therapeutics 20091201

• Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine.

  Journal of neural transmission (Vienna, Austria : 1996) 20091201

• Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.

  Journal of clinical pharmacy and therapeutics 20091201

• Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.

  Journal of the American Geriatrics Society 20091101

• Hepatitis with cholestasis caused by rivastigmine transdermal patch.

  The American journal of gastroenterology 20091101

• Alzheimer's disease: Seeing the signs early.

  Journal of the American Academy of Nurse Practitioners 20091101

• Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.

  International psychogeriatrics 20091001

• Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors.

  Bioorganic & medicinal chemistry 20090915

• Rivastigmine reverses habituation memory impairment observed in sepsis survivor rats.

  Shock (Augusta, Ga.) 20090901

• Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity.

  Human & experimental toxicology 20090901

• [The possible value of diagnosing MCI-DLB and treatment options].

  Tijdschrift voor gerontologie en geriatrie 20090901

• Chemoenzymatic synthesis of rivastigmine based on lipase-catalyzed processes.

  The Journal of organic chemistry 20090807

• Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.

  European journal of pharmacology 20090801

• Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.

  Pharmacogenetics and genomics 20090801

• Rivastigmine in Parkinson's disease dementia.

  Expert opinion on drug metabolism & toxicology 20090801

• Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

  Acta pharmacologica Sinica 20090701

• Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia.

  The neurologist 20090701

• Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach.

  Gender medicine 20090701

• [Mental handicap].

  Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie 20090701

• Rational design of central selective acetylcholinesterase inhibitors by means of a 'bio-oxidisable prodrug' strategy.

  Organic & biomolecular chemistry 20090621

• Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition.

  Bioorganic & medicinal chemistry letters 20090615

• Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.

  American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 20090605

• [Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)].

  Revista de neurologia 20090601

• A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught?

  Brain injury 20090601

• Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.

  Journal of medical economics 20090601

• Drug-induced sialorrhoea and excessive saliva accumulation.

  Prescrire international 20090601

• [Progressive supranucleair palsy: acetylcholineeserase-inhibitor a possible therapy?].

  Tijdschrift voor gerontologie en geriatrie 20090601

• Treatment of Alzheimer's disease in the long-term-care setting.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090515

• Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery--a randomized controlled trial.

  Critical care medicine 20090501

• Cholinergic modulation of MEG resting-state oscillatory activity in Parkinson's disease related dementia.

  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20090501

• Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.

  International journal of clinical practice 20090501

• Rivastigmine reduces tobacco craving in alcohol-dependent smokers.

  Pharmacopsychiatry 20090501

• Rivastigmine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20090415

• Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.

  Journal of clinical pharmacology 20090401

• [Treatment of degenerative dementia disorders--who should be treated?].

  Ugeskrift for laeger 20090302

• Long-term rivastigmine treatment in a routine clinical setting.

  Acta neurologica Scandinavica 20090301

• Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines.

  Translational research : the journal of laboratory and clinical medicine 20090301

• Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.

  Neuroreport 20090218

• BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.

  Movement disorders : official journal of the Movement Disorder Society 20090215

• Top cited papers in International Psychogeriatrics: 1. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.

  International psychogeriatrics 20090201

• Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.

  Electrophoresis 20090201

• Long-term effects of rivastigmine capsules in patients with traumatic brain injury.

  Brain injury 20090201

• Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

  Current Alzheimer research 20090201

• Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.

  Journal of the American Geriatrics Society 20090201

• Rivastigmine for dementia in people with Down syndrome.

  The Cochrane database of systematic reviews 20090121

• Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions.

  The Biochemical journal 20090101

• Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine.

  Psychopharmacology 20090101

• Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine.

  The journal of nutrition, health & aging 20090101

• [The role of rivastigmine (exelon) in the treatment of consequences of cranial-brain trauma].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].

  Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater 20090101

• Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex.

  Journal of Alzheimer's disease : JAD 20090101

• Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease.

  American journal of Alzheimer's disease and other dementias 20090101

• Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20090101

• Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.

  Alzheimer disease and associated disorders 20090101

• Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.

  Drugs & aging 20090101

• [Results of the open multicenter prospective study of safety and tolerability of rivastigmine (exelon) in different titration regimes in mild and moderate Alzheimer's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?

  Dementia and geriatric cognitive disorders 20090101

• Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect.

  The Journal of neuropsychiatry and clinical neurosciences 20090101

• Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.

  Clinical drug investigation 20090101

• Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.

  Dementia and geriatric cognitive disorders 20090101

• Gender differences in the pharmacokinetics of rivastigmine in rats.

  Arzneimittel-Forschung 20090101

• Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?

  Neurologia i neurochirurgia polska 20090101

• Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.

  Expert opinion on drug delivery 20081201

• Brain cholinergic impairment in liver failure.

  Brain : a journal of neurology 20081101

• Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine.

  Journal of neuroimmunology 20081015

• Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

  Journal of neural transmission (Vienna, Austria : 1996) 20081001

• Pharmacological treatment in moderate-to-severe Alzheimer's disease.

  Expert opinion on pharmacotherapy 20081001

• Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers.

  The international journal of neuropsychopharmacology 20080901

• Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.

  Current medical research and opinion 20080901

• [Alzheimer type dementia].

  Revue de l'infirmiere 20080901

• Effects of rivastigmine on memory and cognition in multiple sclerosis.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080901

• Drug utilization review of cholinesterase inhibitors in Quebec.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080901

• [A transdermal patch of rivastigmine (Exelon)].

  Revue medicale de Liege 20080901

• A study of rivastigmine liposomes for delivery into the brain through intranasal route.

  Acta pharmaceutica (Zagreb, Croatia) 20080901

• Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.

  Movement disorders : official journal of the Movement Disorder Society 20080815

• Rivastigmine in Parkinson's disease dementia.

  Expert review of neurotherapeutics 20080801

• Rivastigmine transdermal patch: role in the management of Alzheimer's disease.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080801

• Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.

  Pharmacoepidemiology and drug safety 20080701

• Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease.

  Psychopharmacology 20080601

• Complete atrioventricular block associated with rivastigmine therapy.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080601

• Miniaturized membrane sensors for the determination of rivastigmine hydrogen tartrate.

  Chemical & pharmaceutical bulletin 20080601

• Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

  Journal of managed care pharmacy : JMCP 20080601

• [A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study].

  Revista de neurologia 20080501

• Dementia medications in palliative care #174.

  Journal of palliative medicine 20080501

• [Treatment of Alzheimer's disease: status quo and future considerations].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080501

• Parkinson's disease in the elderly.

  Medicine and health, Rhode Island 20080501

• Diagnosis and treatment of dementia with Lewy bodies.

  JAAPA : official journal of the American Academy of Physician Assistants 20080501

• AAFP and ACP release guideline on dementia treatment.

  American family physician 20080415

• In situ-forming oleogel implant for rivastigmine delivery.

  Pharmaceutical research 20080401

• Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20080401

• The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers.

  Pharmacology, biochemistry, and behavior 20080401

• A rivastigmine patch for dementia.

  The Medical letter on drugs and therapeutics 20080324

• Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.

  Brain research 20080320

• A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization.

  Macromolecular bioscience 20080310

• Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.

  Annals of internal medicine 20080304

• Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

  Annals of internal medicine 20080304

• Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

  Annals of internal medicine 20080304

• Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.

  Pharmacotherapy 20080301

• Microcalorimetric study of the inhibition of butyrylcholinesterase by carbamates.

  Analytical biochemistry 20080215

• Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

  International journal of geriatric psychiatry 20080201

• A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.

  International journal of geriatric psychiatry 20080201

• Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.

  International journal of geriatric psychiatry 20080201

• Neurological signs in relation to type of cerebrovascular disease in vascular dementia.

  Stroke 20080201

• Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.

  Journal of clinical pharmacology 20080201

• Pharmacologic management of Alzheimer disease.

  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20080201

• [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080131

• Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

  Clinical pharmacology and therapeutics 20080101

• [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].

  Der Nervenarzt 20080101

• Rivastigmine in Wernicke-Korsakoff's syndrome: five patients with rivastigmine showed no more improvement than five patients without rivastigmine.

  Alcohol and alcoholism (Oxford, Oxfordshire) 20080101

• Identification of responders to rivastigmine: a prospective cohort study.

  Dementia and geriatric cognitive disorders 20080101

• A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders.

  Current medical research and opinion 20080101

• Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.

  Drug safety 20080101

• Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia.

  American journal of Alzheimer's disease and other dementias 20080101

• Estimated pre-morbid IQ effects on cognitive and functional outcomes in Alzheimer disease: a longitudinal study in a treated cohort.

  BMC psychiatry 20080101

• Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.

  Clinical drug investigation 20080101

• Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.

  Drugs & aging 20080101

• Fluorimetric determination of rivastigmine in rat plasma by a reverse phase--high performance liquid chromatographic method. Application to a pharmacokinetic study.

  Arzneimittel-Forschung 20080101

• Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

  Clinical interventions in aging 20080101

• A pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative.

  BMC neurology 20080101

• [The treatment of Alzheimer's disease in patients with comorbid somatic pathology].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20080101

• Student pharmacists: don't forget the product labeling.

  Journal of the American Pharmacists Association : JAPhA 20080101

• A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy.

  Arzneimittel-Forschung 20080101

• Discontinuing Alzheimer's disease drug therapy: why, when, and how.

  Director (Cincinnati, Ohio) 20080101

• Focusing effect of acetylcholine on neuroplasticity in the human motor cortex.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20071226

• Rivastigmine exposure provided by a transdermal patch versus capsules.

  Current medical research and opinion 20071201

• Rivastigmine-induced dystonia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071201

• Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.

  Psychiatry and clinical neurosciences 20071201

• [Rivastigmine against dementia in Parkinson disease?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20071115

• A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.

  Expert review of neurotherapeutics 20071101

• N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.

  European journal of pharmacology 20071031

• Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.

  Journal of neurology, neurosurgery, and psychiatry 20071001

• Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates.

  International journal of geriatric psychiatry 20071001

• [Lewy body dementia and Parkinson disease dementia].

  Presse medicale (Paris, France : 1983) 20071001

• Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.

  Current medical research and opinion 20071001

• Evaluation of centrally acting cholinesterase inhibitor exposures in adults.

  The Annals of pharmacotherapy 20071001

• Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.

  Journal of clinical psychopharmacology 20071001

• Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20071001

• Diagnosis and management of vascular cognitive impairment.

  Current atherosclerosis reports 20071001

• [Are anti-dementia drugs worthwhile?].

  MMW Fortschritte der Medizin 20070913

• Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.

  International journal of geriatric psychiatry 20070901

• Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.

  The Lancet. Neurology 20070901

• NICE judgement leaves behind a nasty taste.

  Nursing older people 20070901

• Pharmacokinetic rationale for the rivastigmine patch.

  Neurology 20070724

• IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

  Neurology 20070724

• Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.

  Neurology 20070724

• Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study.

  Neurology 20070703

• Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.

  Journal of Alzheimer's disease : JAD 20070701

• A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601

• The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.

  Molecular pharmacology 20070601

• Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.

  International psychogeriatrics 20070601

• EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.

  International journal of clinical practice 20070601

• MCI treatment trials: failure or not?

  The Lancet. Neurology 20070601

• Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.

  The Lancet. Neurology 20070601

• [Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies].

  Deutsche medizinische Wochenschrift (1946) 20070601

• [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].

  Revista de neurologia 20070601

• Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.

  Drugs of today (Barcelona, Spain : 1998) 20070601

• [Acetylcholinesterase inhibitors for dementia--an update].

  MMW Fortschritte der Medizin 20070521

• Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

  Neurology 20070515

• Effects of rivastigmine on cognitive function in patients with traumatic brain injury.

  Neurology 20070515

• Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.

  Pharmacoepidemiology and drug safety 20070501

• Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.

  Psychopharmacology 20070501

• A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.

  International journal of geriatric psychiatry 20070501

• Effect of anti-dementia drugs on LPS induced neuroinflammation in mice.

  Life sciences 20070501

• Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.

  International journal of geriatric psychiatry 20070501

• [Hallucinations associated to treatment with rivastigmine in two patients with diffuse Lewy body disease].

  Revista de neurologia 20070501

• Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.

  Journal of the American Geriatrics Society 20070501

• Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.

  International journal of geriatric psychiatry 20070401

• Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.

  International journal of geriatric psychiatry 20070401

• Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application.

  Journal of clinical pharmacology 20070401

• Rivastigmine and Parkinson dementia complex.

  Expert opinion on pharmacotherapy 20070401

• Modulation of human motor cortex excitability by the cholinesterase inhibitor rivastigmine.

  Neuroscience letters 20070319

• The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease.

  Journal of the American Medical Directors Association 20070301

• Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.

  Current medical research and opinion 20070301

• Rivastigmine in the treatment of Alzheimer's disease: an update.

  Clinical interventions in aging 20070301

• [Synthesis of S-(+)-rivastigmine hydrogentartrate].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070201

• Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.

  Archives of gerontology and geriatrics 20070101

• Strategies to improve tolerability of rivastigmine: a case series.

  Current medical research and opinion 20070101

• Two years' follow-up of rivastigmine treatment in Huntington disease.

  Clinical neuropharmacology 20070101

• Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).

  Archives of gerontology and geriatrics 20070101

• Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.

  Dementia and geriatric cognitive disorders 20070101

• Rivastigmine in Parkinson's disease dementia: profile report.

  Drugs & aging 20070101

• Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.

  American journal of Alzheimer's disease and other dementias 20070101

• [Transdermal drugs in neurology].

  Neurologia (Barcelona, Spain) 20070101

• Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series.

  Neurologia i neurochirurgia polska 20070101

• Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances.

  Functional neurology 20070101

• Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type.

  Pharmacological reports : PR 20070101

• Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease.

  Advances in therapy 20070101

• Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.

  Acta bio-medica : Atenei Parmensis 20070101

• Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease.

  Acta neurobiologiae experimentalis 20070101

• Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

  PharmacoEconomics 20070101

• Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.

  CNS drugs 20070101

• Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).

  Drug safety 20070101

• Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.

  Current medicinal chemistry 20070101

• Neuropsychological rehabilitation in mild and moderate Alzheimer's disease patients.

  Behavioural neurology 20070101

• The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.

  British journal of pharmacology 20061201

• [Diagnosis and clinical therapy for Parkinson's disease].

  Der Nervenarzt 20061201

• Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.

  Journal of child and adolescent psychopharmacology 20061201

• 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry letters 20061115

• Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.

  Journal of neural transmission (Vienna, Austria : 1996) 20061101

• Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20061101

• Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.

  Pharmacogenetics and genomics 20061101

• A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.

  Current medical research and opinion 20061101

• Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

  Journal of psychiatry & neuroscience : JPN 20061101

• [Medical treatment of Alzheimer's disease].

  Ugeskrift for laeger 20061002

• Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.

  Movement disorders : official journal of the Movement Disorder Society 20061001

• [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].

  Revista de neurologia 20061001

• Use of antidementia agents in vascular dementia: beyond Alzheimer disease.

  Mayo Clinic proceedings 20061001

• Unsubstantiated superiority claims for rivastigmine tartrate.

  The Journal of the American Osteopathic Association 20061001

• Effects of rivastigmine on cognitive function in patients with traumatic brain injury.

  Neurology 20060912

• Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.

  Acta pharmacologica Sinica 20060901

• Do caregivers' experiences correspond with the concerns raised in the literature? Ethical issues relating to anti-dementia drugs.

  International journal of geriatric psychiatry 20060901

• Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.

  Journal of neurology 20060901

• [Advances in Alzheimer's disease treatment].

  La Revue de medecine interne 20060801

• [Cholinesterase inhibitor therapy in long term care settings].

  La Revue de medecine interne 20060801

• Alzheimer's disease.

  Lancet (London, England) 20060729

• Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial.

  Progress in neuro-psychopharmacology & biological psychiatry 20060701

• Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.

  Schizophrenia research 20060701

• Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20060701

• [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].

  Tijdschrift voor gerontologie en geriatrie 20060701

• Antipsychotic drug use among nursing home residents taking rivastigmine.

  Journal of the American Medical Directors Association 20060601

• Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.

  International journal of clinical practice 20060601

• Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.

  International journal of clinical practice 20060601

• Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

  The American journal of geriatric pharmacotherapy 20060601

• Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

  Movement disorders : official journal of the Movement Disorder Society 20060401

• Clinical trials in mild cognitive impairment: lessons for the future.

  Journal of neurology, neurosurgery, and psychiatry 20060401

• Pharmacological manipulation of the vasoconstrictive effects of amyloid-beta peptides by donepezil and rivastigmine.

  Current Alzheimer research 20060401

• Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.

  Journal of geriatric psychiatry and neurology 20060301

• Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: application to mild and moderate dementia.

  The Nursing clinics of North America 20060301

• Appeals system and its outcomes in national health insurance in Taiwan.

  The Annals of pharmacotherapy 20060301

• Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.

  Current medical research and opinion 20060301

• Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus.

  Brain research 20060216

• Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20060201

• Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.

  Mechanisms of ageing and development 20060201

• Quetiapine and rivastigmine for agitation in Alzheimer's disease.

  Current psychiatry reports 20060201

• Cholinesterase inhibitors for Parkinson's disease dementia.

  The Cochrane database of systematic reviews 20060125

• Cholinesterase inhibitors for Alzheimer's disease.

  The Cochrane database of systematic reviews 20060125

• Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.

  NeuroImage 20060115

• A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

  International journal of geriatric psychiatry 20060101

• Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.

  International journal of geriatric psychiatry 20060101

• Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression.

  Emergency medicine journal : EMJ 20060101

• Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.

  Dementia and geriatric cognitive disorders 20060101

• Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

  Current medical research and opinion 20060101

• Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.

  International journal of clinical practice 20060101

• The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

  Health technology assessment (Winchester, England) 20060101

• Antipsychotic drug use among nursing home residents taking rivastigmine.

  Journal of the American Medical Directors Association 20060101

• Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.

  PharmacoEconomics 20060101

• Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.

  Pharmacopsychiatry 20060101

• QEEG monitoring of Alzheimer's disease treatment: a preliminary report of three case studies.

  Clinical EEG and neuroscience 20060101

• A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.

  Drugs & aging 20060101

• Current and emerging pharmacological treatment options for dementia.

  Behavioural neurology 20060101

• Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.

  Alzheimer disease and associated disorders 20060101

• Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.

  Drugs & aging 20060101

• Rivastigmine: in Parkinson's disease dementia.

  CNS drugs 20060101

• [Pharmacotherapy for Alzheimer's disease].

  Tijdschrift voor psychiatrie 20060101

• Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.

  The Journal of international medical research 20060101

• Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

  CNS drugs 20060101

• A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.

  Rapid communications in mass spectrometry : RCM 20060101

• Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients.

  Drug safety 20060101

• Realistic expectations for treatment success in Alzheimer's disease.

  The journal of nutrition, health & aging 20060101

• [Pharmacological approaches to the therapy of Alzheimer's disease].

  Vestnik Rossiiskoi akademii meditsinskikh nauk 20060101

• Alzheimer disease and its management: a review.

  American journal of therapeutics 20060101

• Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.

  Alzheimer disease and associated disorders 20060101

• First treatment for dementia of Parkinson's disease.

  FDA consumer 20060101

• Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.

  The Journal of pharmacology and experimental therapeutics 20051201

• Discontinuation of rivastigmine in routine clinical practice.

  International journal of geriatric psychiatry 20051201

• Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study.

  Clinical rehabilitation 20051201

• Dementia.

  Clinical evidence 20051201

• Benefits of rivastigmine on attention in dementia associated with Parkinson disease.

  Neurology 20051122

• Behavioral and neuropsychiatric outcomes in Alzheimer's disease.

  CNS spectrums 20051101

• Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.

  Current medical research and opinion 20051101

• Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.

  Brain research 20051026

• The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.

  British journal of pharmacology 20051001

• Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.

  Current medical research and opinion 20051001

• Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects.

  Psychopharmacology 20050901

• Rivastigmine for Alzheimer's disease.

  Expert review of neurotherapeutics 20050901

• UK government guidance on Alzheimer's drugs postponed.

  Drug discovery today 20050901

• Efficacy of rivastigmine on activities of daily living in Sri Lankan patients with Alzheimer disease and on improving caregiver burden: a prospective study.

  The Ceylon medical journal 20050901

• Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.

  The American journal of geriatric pharmacotherapy 20050901

• Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

  BMJ (Clinical research ed.) 20050806

• One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.

  Human psychopharmacology 20050801

• Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study.

  Journal of clinical psychopharmacology 20050801

• Neurophysiological predictors of long term response to AChE inhibitors in AD patients.

  Journal of neurology, neurosurgery, and psychiatry 20050801

• Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

  Current medical research and opinion 20050801

• Pesticide-like poisoning from a prescription drug.

  The New England journal of medicine 20050721

• Enantioselective separation of rivastigmine by capillary electrophoresis with cyclodextrines.

  Journal of chromatography. A 20050715

• A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.

  European journal of clinical pharmacology 20050701

• Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.

  International journal of clinical practice 20050701

• Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.

  Journal of neurology, neurosurgery, and psychiatry 20050701

• Rivastigmine for dementia associated with Parkinson's disease.

  Current neurology and neuroscience reports 20050701

• [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].

  Tijdschrift voor gerontologie en geriatrie 20050701

• Treatment persistency with rivastigmine and donepezil in a large state medicaid program.

  Journal of the American Geriatrics Society 20050701

• A validated chiral liquid chromatographic method for the enantiomeric separation of Rivastigmine hydrogen tartarate, a cholinesterase inhibitor.

  Journal of pharmaceutical and biomedical analysis 20050615

• Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.

  Psychopharmacology 20050601

• A study paradigm allowing comparison of multiple high-resolution rCBV-maps for the examination of drug effects.

  NMR in biomedicine 20050601

• [Changing the anticholinesterase in Alzheimer's disease].

  Revista de neurologia 20050601

• Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.

  Annals of neurology 20050501

• Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome.

  International journal of geriatric psychiatry 20050501

• Rivastigmine for subcortical vascular dementia.

  Expert review of neurotherapeutics 20050501

• Rivastigmine for vascular cognitive impairment.

  The Cochrane database of systematic reviews 20050418

• Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.

  BMJ (Clinical research ed.) 20050416

• Drugs for Alzheimer's disease and related dementias.

  BMJ (Clinical research ed.) 20050416

• Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.

  Journal of managed care pharmacy : JMCP 20050401

• Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.

  International journal of clinical practice 20050401

• Rivastigmine for dementia associated with Parkinson's disease.

  The New England journal of medicine 20050331

• NICE proposes to withdraw Alzheimer's drugs from NHS.

  BMJ (Clinical research ed.) 20050305

• Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease.

  The Lancet. Neurology 20050301

• Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia.

  Journal of psychopharmacology (Oxford, England) 20050301

• Cholinesterase inhibitors in the treatment of dementia.

  The Journal of the American Osteopathic Association 20050301

• Effects of rivastigmine in a case of residual schizophrenia.

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20050301

• Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.

  Journal of the American Academy of Nurse Practitioners 20050301

• Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.

  European journal of pharmacology 20050221

• Seizures associated with memantine use.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050215

• A stability indicating LC method for rivastigmine hydrogen tartrate.

  Journal of pharmaceutical and biomedical analysis 20050207

• Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression.

  Dementia and geriatric cognitive disorders 20050101

• A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20050101

• Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.

  Progress in neuro-psychopharmacology & biological psychiatry 20050101

• Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.

  Dementia and geriatric cognitive disorders 20050101

• Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.

  BMC geriatrics 20050101

• Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

  Dementia and geriatric cognitive disorders 20050101

• Dementia treatment update.

  Geriatric nursing (New York, N.Y.) 20050101

• Heterocyclic inhibitors of AChE acylation and peripheral sites.

  Farmaco (Societa chimica italiana : 1989) 20050101

• [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

• The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease.

  Journal of the American Medical Directors Association 20050101

• The impact of acetylcholinergic medications on Alzheimer's disease-related behavioral disorders in nursing home patients: what is the real impact?

  Journal of the American Medical Directors Association 20050101

• Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.

  Drugs & aging 20050101

• Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.

  Dementia and geriatric cognitive disorders 20050101

• Drug therapy of dementia in elderly patients. A review.

  Nordic journal of psychiatry 20050101

• The potential value of negative studies.

  Journal of the American Medical Directors Association 20050101

• Short-term treatment with rivastigmine and plasma levels of Abeta peptides in Alzheimer's disease.

  Folia neuropathologica 20050101

• Poisoning with rivastigmine.

  Clinical toxicology (Philadelphia, Pa.) 20050101

• [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].

  Revista espanola de salud publica 20050101

• Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.

  Neurology 20041228

• Rivastigmine for dementia associated with Parkinson's disease.

  The New England journal of medicine 20041209

• Parkinson's disease dementia--a first step?

  The New England journal of medicine 20041209

• [Dementia-current knowledge and significance for ENT specialists].

  HNO 20041201

• Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.

  Movement disorders : official journal of the Movement Disorder Society 20041201

• Dementia.

  Clinical evidence 20041201

• [Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].

  Nederlands tijdschrift voor geneeskunde 20041127

• Impact of APOE in mild cognitive impairment.

  Neurology 20041123

• Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.

  Journal of medicinal chemistry 20041118

• Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.

  Journal of the neurological sciences 20041115

• [Are there innovations in the treatment of Parkinson's disease?].

  Praxis 20041103

• Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia.

  The Annals of pharmacotherapy 20041101

• Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living.

  International clinical psychopharmacology 20041101

• Switching from donepezil or rivastigmine to galantamine in clinical practice.

  Journal of the American Geriatrics Society 20041101

• An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

  Current medical research and opinion 20041101

• Fluctuations in cognition and alertness in Parkinson's disease and dementia.

  Neurology 20041026

• Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.

  European journal of pharmacology 20041025

• [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].

  Nederlands tijdschrift voor geneeskunde 20041023

• Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.

  Current medical research and opinion 20041001

• Evidence-based pharmacotherapy of Alzheimer's disease.

  The international journal of neuropsychopharmacology 20040901

• Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.

  Neuropharmacology 20040901

• Adding rivastigmine to antipsychotics in the treatment of a chronic delirium.

  Age and ageing 20040901

• The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.

  Expert opinion on drug safety 20040901

• [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].

  Revista de neurologia 20040801

• [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].

  Nederlands tijdschrift voor geneeskunde 20040724

• Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040705

• A case study in the treatment of dementia with Lewy bodies.

  Acta psychiatrica Scandinavica 20040701

• Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.

  CNS spectrums 20040701

• Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage.

  International journal of geriatric psychiatry 20040701

• Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.

  Clinical therapeutics 20040701

• Absorption of rivastigmine from different regions of the gastrointestinal tract in humans.

  Journal of clinical pharmacology 20040601

• Rivastigmine in vascular dementia.

  Expert opinion on pharmacotherapy 20040601

• Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.

  International journal of geriatric psychiatry 20040601

• Dementia.

  Clinical evidence 20040601

• Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.

  Neuroscience letters 20040506

• Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20040501

• Behavioral symptoms in mild cognitive impairment.

  Neurology 20040413

• Emerging therapies for vascular dementia and vascular cognitive impairment.

  Stroke 20040401

• Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease.

  Journal of neurology, neurosurgery, and psychiatry 20040401

• Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.

  European journal of neurology 20040401

• A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry.

  Biomedical chromatography : BMC 20040401

• Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.

  International journal of clinical practice 20040401

• Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.

  Journal of neurochemistry 20040301

• Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.

  International journal of geriatric psychiatry 20040301

• Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.

  Journal of child neurology 20040301

• Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging.

  Stroke 20040201

• Prediction of treatment response to rivastigmine in Alzheimer's dementia.

  Journal of neurology, neurosurgery, and psychiatry 20040201

• Pharmacologic treatment expectations in the management of dementia with Lewy bodies.

  Dementia and geriatric cognitive disorders 20040101

• Acetylcholinesterase inhibition in Alzheimer's Disease.

  Current pharmaceutical design 20040101

• Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

  Drugs & aging 20040101

• Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies.

  Dementia and geriatric cognitive disorders 20040101

• Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer's Caregiver Health (REACH) project.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101

• Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study.

  Archives of gerontology and geriatrics. Supplement 20040101

• What are the treatment options for patients with severe Alzheimer's disease?

  CNS drugs 20040101

• The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?

  Journal of the American Medical Directors Association 20040101

• Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.

  Dementia and geriatric cognitive disorders 20040101

• Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101

• Rivastigmine in Alzheimer disease: efficacy over two years.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101

• Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.

  Alzheimer disease and associated disorders 20040101

• Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease?

  Neuroepidemiology 20040101

• Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.

  The pharmacogenomics journal 20040101

• Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease.

  Clinical neuropharmacology 20040101

• Disease stage in Alzheimer disease and treatment effects of rivastigmine.

  Alzheimer disease and associated disorders 20040101

• Rivastigmine in frontotemporal dementia: an open-label study.

  Drugs & aging 20040101

• Impact of rivastigmine use on the risk of nursing home placement in a US sample.

  CNS drugs 20040101

• The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.

  The Journal of neuropsychiatry and clinical neurosciences 20040101

• Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients.

  American journal of Alzheimer's disease and other dementias 20040101

• [The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years].

  Neurologia i neurochirurgia polska 20040101

• The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.

  Journal of the neurological sciences 20031215

• Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine.

  Brain : a journal of neurology 20031201

• A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20031201

• Nightmares without atonia as an early symptom of diffuse Lewy bodies disease.

  Arquivos de neuro-psiquiatria 20031201

• Italian drug policy: ethical aims of essential assistance levels.

  Health care analysis : HCA : journal of health philosophy and policy 20031201

• Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.

  International psychogeriatrics 20031201

• Rivastigmine blocks voltage-activated K+ currents in dissociated rat hippocampal neurons.

  British journal of pharmacology 20031101

• Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.

  Acta neurologica Scandinavica 20031101

• Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.

  Pharmacopsychiatry 20031101

• Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.

  International journal of clinical practice 20031101

• [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].

  Presse medicale (Paris, France : 1983) 20031025

• Editorial comment--How to treat vascular dementia?

  Stroke 20031001

• Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.

  Journal of the American Geriatrics Society 20030901

• [Subcortical vascular encephalopathy].

  Therapeutische Umschau. Revue therapeutique 20030901

• Update on rivastigmine.

  The neurologist 20030901

• Influence of cholinergic circuitries in generation of high-frequency somatosensory evoked potentials.

  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20030801

• [Acetylcholinesterase inhibitors].

  Revue medicale de la Suisse romande 20030701

• Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.

  Neuroscience letters 20030612

• Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

  The Journal of pharmacology and experimental therapeutics 20030601

• The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.

  Journal of neural transmission (Vienna, Austria : 1996) 20030601

• Rivastigmine and QT interval prolongation.

  The British journal of psychiatry : the journal of mental science 20030601

• Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.

  International journal of geriatric psychiatry 20030601

• Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

  Archives of neurology 20030601

• Comparative study of donepezil and rivastigmine.

  International journal of clinical practice 20030601

• A review of rivastigmine: a reversible cholinesterase inhibitor.

  Clinical therapeutics 20030601

• Dementia.

  Clinical evidence 20030601

• [Current therapy of patients with dementia].

  MMW Fortschritte der Medizin 20030526

• Surprising discovery with Alzheimer's medication.

  Drug discovery today 20030501

• [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].

  Nederlands tijdschrift voor geneeskunde 20030405

• [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].

  Nederlands tijdschrift voor geneeskunde 20030405

• Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.

  Acta neurologica Scandinavica 20030401

• [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].

  Fortschritte der Neurologie-Psychiatrie 20030401

• Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.

  International clinical psychopharmacology 20030301

• [Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period].

  Revista de neurologia 20030301

• Rivastigmine in the treatment of alcohol-induced persisting dementia.

  The West Indian medical journal 20030301

• Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.

  Neuroscience letters 20030227

• Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205

• Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.

  Journal of the neurological sciences 20030115

• No additional benefit of HRT on response to rivastigmine in menopausal women with AD.

  Neurology 20030114

• [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].

  Nederlands tijdschrift voor geneeskunde 20030104

• Comparative study of donepezil and rivastigmine.

  International journal of clinical practice 20030101

• The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease.

  Gerontology 20030101

• Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.

  Current medical research and opinion 20030101

• Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.

  Current medical research and opinion 20030101

• Cholinesterase inhibitors for dementia with Lewy bodies.

  The Cochrane database of systematic reviews 20030101

• Current treatments for Alzheimer's disease: cholinesterase inhibitors.

  The Journal of clinical psychiatry 20030101

• Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.

  Acta biologica Hungarica 20030101

• Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.

  American journal of Alzheimer's disease and other dementias 20030101

• [Mechanisms of action of Alzheimer medications].

  Duodecim; laaketieteellinen aikakauskirja 20030101

• Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia.

  Clinical neuropharmacology 20030101

• Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.

  Current medical research and opinion 20030101

• No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.

  Current medical research and opinion 20030101

• Rivastigmine in vascular dementia.

  International psychogeriatrics 20030101

• [Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].

  Fortschritte der Medizin. Originalien 20021205

• Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.

  Journal of neurology, neurosurgery, and psychiatry 20021201

• Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.

  Journal of clinical psychopharmacology 20021201

• Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.

  International journal of clinical practice 20021201

• [Ethical aspects of anti-Alzheimer drugs: experiences of caregivers].

  Tijdschrift voor gerontologie en geriatrie 20021201

• Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.

  European journal of pharmacology 20021129

• Rivastigmine in subcortical vascular dementia: an open 22-month study.

  Journal of the neurological sciences 20021115

• [Rivastigmine: a review of its clinical effectiveness].

  Revista de neurologia 20021101

• Rivastigmine in the treatment of Huntington's disease.

  European journal of neurology 20021101

• [Anti-dementia drugs for Alzheimer disease in present and future].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20021101

• Fatal aspiration pneumonia during transition from donepezil to rivastigmine.

  The Annals of pharmacotherapy 20021001

• The impact of journal advertisements on prescribers of cholinesterase inhibitors.

  International journal of geriatric psychiatry 20021001

• [Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].

  Revue neurologique 20020901

• Electroconvulsive therapy in a patient receiving rivastigmine.

  The journal of ECT 20020901

• Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20020901

• Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.

  Neurology 20020827

• Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation.

  Neurology 20020813

• Clinical use of cholinomimetic agents: a review.

  The Journal of head trauma rehabilitation 20020801

• Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20020801

• Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.

  Journal of neural transmission (Vienna, Austria : 1996) 20020701

• Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.

  Journal of neural transmission (Vienna, Austria : 1996) 20020701

• Medical treatment of Alzheimer's disease: past, present, and future.

  Medicine and health, Rhode Island 20020701

• Guidelines for managing Alzheimer's disease: Part II. Treatment.

  American family physician 20020615

• Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

  Clinical therapeutics 20020601

• The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.

  International journal of clinical practice. Supplement 20020601

• Do cholinesterase inhibitors slow progression of Alzheimer's disease?

  International journal of clinical practice. Supplement 20020601

• The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

  International journal of clinical practice. Supplement 20020601

• Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease.

  International psychogeriatrics 20020601

• Prolonged QT interval with rivastigmine.

  The British journal of psychiatry : the journal of mental science 20020501

• Electrocardiographic effects of rivastigmine.

  Journal of clinical pharmacology 20020501

• Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

  Progress in neuro-psychopharmacology & biological psychiatry 20020501

• Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.

  Progress in neuro-psychopharmacology & biological psychiatry 20020501

• A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.

  International journal of geriatric psychiatry 20020401

• The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.

  International journal of clinical practice 20020401

• Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

  Biochemistry 20020319

• [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].

  Nederlands tijdschrift voor geneeskunde 20020309

• Rivastigmine in outpatient services: experience of 114 neurologists in Austria.

  International clinical psychopharmacology 20020301

• Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?

  International journal of geriatric psychiatry 20020301

• Understanding changes in cholinergic function: implications for treating dementia.

  The Journal of clinical psychiatry 20020301

• Rivastigmin and impaired motor function.

  Pharmacopsychiatry 20020301

• [Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report].

  Arquivos de neuro-psiquiatria 20020301

• Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.

  European journal of medicinal chemistry 20020201

• An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.

  Medical science monitor : international medical journal of experimental and clinical research 20020201

• Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.

  Neuroreport 20020121

• [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].

  Nederlands tijdschrift voor geneeskunde 20020105

• Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

  European neurology 20020101

• Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system.

  Dementia and geriatric cognitive disorders 20020101

• In vitro toxicity of rivastigmine and donepezil in cells of epithelial origin.

  Ophthalmic research 20020101

• Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.

  Clinical pharmacokinetics 20020101

• Cutaneous drug reaction case reports: from the world literature.

  American journal of clinical dermatology 20020101

• Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine.

  Clinical neuropharmacology 20020101

• Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.

  Current medical research and opinion 20020101

• Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.

  Current medical research and opinion 20020101

• Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

  Clinical pharmacokinetics 20020101

• Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?

  International journal of clinical practice 20020101

• A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.

  International journal of clinical practice 20020101

• Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis.

  Neuroscience 20020101

• Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.

  Current medical research and opinion 20020101

• Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

  International journal of technology assessment in health care 20020101

• Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.

  Current medical research and opinion 20020101

• Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

  Clinical neuropharmacology 20020101

• A clinical overview of cholinesterase inhibitors in Alzheimer's disease.

  International psychogeriatrics 20020101

• [Acetylcholinesterase inhibitors--beyond Alzheimer's disease].

  Psychiatria polska 20020101

• Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine.

  European journal of pharmacology 20011214

• [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].

  MMW Fortschritte der Medizin 20011213

• [Perspectives for drug treatment in Alzheimer's disease].

  Annales de medecine interne 20011201

• [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].

  Fortschritte der Medizin. Originalien 20011129

• Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.

  Mechanisms of ageing and development 20011101

• Erythematous maculopapular eruption due to rivastigmine therapy.

  The American journal of medicine 20011101

• Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.

  Movement disorders : official journal of the Movement Disorder Society 20011101

• Adverse reactions to rivastigmine in three cases of dementia.

  The Australian and New Zealand journal of psychiatry 20011001

• Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.

  Journal of clinical pharmacology 20011001

• Acetylcholinesterase inhibitor SDZ ENA 713 (Rivastigmine) increases brain pyrrolidone carboxyl peptidase activity.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20011001

• Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

  The international journal of neuropsychopharmacology 20010901

• [Anticholinesterase agents in Alzheimer's disease].

  Revue medicale de Bruxelles 20010901

• Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep.

  International psychogeriatrics 20010901

• Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.

  Mini reviews in medicinal chemistry 20010901

• Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels.

  Brain research 20010810

• Medications for the treatment of Alzheimer's disease.

  The Journal of the Oklahoma State Medical Association 20010801

• Maintaining functional and behavioral abilities in Alzheimer disease.

  Alzheimer disease and associated disorders 20010801

• Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up.

  European journal of neurology 20010701

• Use of cholinesterase inhibitors for treatment of Alzheimer disease.

  Cleveland Clinic journal of medicine 20010701

• Featured CME topic: dementia. Medication update.

  Southern medical journal 20010701

• Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.

  International psychogeriatrics 20010601

• Rivastagmine-induced agitation following transient recollection of autobiographical memory.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20010601

• Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.

  Expert opinion on pharmacotherapy 20010401

• Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

  Archives of neurology 20010301

• Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine.

  Age and ageing 20010301

• [Evaluation of the therapeutic effects in individual patients with Alzheimer disease].

  Nederlands tijdschrift voor geneeskunde 20010224

• Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.

  Journal of clinical psychopharmacology 20010201

• Brief review: rivastigmine, a second cholinesterase inhibitor.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20010201

• Cholinesterase inhibitors for Alzheimer's disease.

  Drugs 20010101

• Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

  Health technology assessment (Winchester, England) 20010101

• Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

  Clinical neuropharmacology 20010101

• Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

  PharmacoEconomics 20010101

• Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.

  Neuropsychobiology 20010101

• Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.

  Clinical therapeutics 20010101

• [Current strategies of pathogenetic therapy of Alzheimer's disease].

  Vestnik Rossiiskoi akademii meditsinskikh nauk 20010101

• Rivastigmine in the treatment of Alzheimer's disease.

  European neurology 20010101

• Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.

  Neurologia i neurochirurgia polska 20010101

• Drugs used for cognitive symptoms of Alzheimer's disease.

  Perspectives in psychiatric care 20010101

• Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.

  Japanese journal of pharmacology 20001001

• Relation between cholinesterase inhibitor and Pisa syndrome.

  Lancet (London, England) 20000624

• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  BMJ (Clinical research ed.) 19990306